查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2018734

心房中膈缺損症市場：2026-2032年全球市場預測（依產品類型、治療方法、年齡層、最終用戶及缺損類型分類）

Atrial Septal Defect Market by Product Type, Treatment Type, Age Group, End User, Defect Type - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年心房中膈缺損症市場價值為 42.7 億美元，預計到 2026 年將成長至 45.8 億美元，複合年成長率為 7.53%，到 2032 年將達到 71 億美元。

主要市場統計數據
基準年 2025 42.7億美元
預計年份：2026年 45.8億美元
預測年份：2032年 71億美元
複合年成長率 (%) 7.53%

我們深入研究了臨床、技術和患者趨勢，為了解心房中膈缺損症市場奠定了基礎。

心房中膈缺損症）是臨床上最常見的先天性心臟疾病之一，其發生與發展涉及血流動力學、解剖結構和患者個體差異等多種因素的複雜相互作用。患有此病的患者臨床表現多種多樣，從無症狀到運動耐受性下降、心律不整和右心室負荷過重均有涉及。這種多樣化的病程凸顯了建立精準診斷途徑和個人化治療性介入的必要性。

在創新、政策演變和以病人為中心的護理策略的推動下，一場變革性的變化正在重塑心房中膈缺損症。

心房中膈缺損症市場正經歷著一場變革，其驅動力包括器材工程技術的突破性進展、醫保報銷模式的轉變以及對以病人為中心的護理模式的日益重視。器械研發人員正透過採用先進的聚合物複合材料和形狀記憶合金，不斷突破小型化和生物相容性的極限，使器械能夠與房間隔的解剖結構完美契合。同時，從遠端血流動力學監測到人工智慧影像分析等數位健康工具的整合，正幫助臨床醫生製定個人化的手術方案並最佳化追蹤流程。

評估 2025 年美國關稅對心臟介入器材供應鏈、成本結構和策略市場定位的影響。

美國於2025年推出的新關稅結構，為心房中膈缺損症治療器材的供應鏈計算引入了一個關鍵變數。逐步對進口零件和成品徵收關稅，導致製造商從原料採購到最終器械組裝的整個流程成本增加。為此，領先的器材製造商正在重新審視籌資策略，並加強與區域供應商的合作，以降低關稅波動帶來的風險，確保零件的持續供應。

ASD 細分市場中有關產品類型、治療方法、年齡層、最終用戶和缺陷類型的關鍵細分見解。

詳細的市場區隔分析揭示了心房中膈缺損症市場的多面性。從產品類型角度來看，該市場包括心肺體外迴圈裝置、封堵器和診斷設備。在封堵解決方案中，封堵器與外科補片並存。前者又可細分為球囊擴張式和自擴張式，而補片則可由生物基或合成材料製成。診斷功能包括心臟導管插入設備、先進影像系統和專用心臟超音波圖平台。這種多層次的層級結構凸顯了針對不同技術叢集進行定向創新的重要性。

闡明北美和南美、歐洲、中東和非洲以及亞太地區心房中膈缺損症市場的區域差異。

心房中膈缺損症領域存在顯著的區域異質性。在美洲，完善的醫保報銷機制、早期採用者以及強大的臨床實驗室網路，共同推動了尖端醫療器材技術的快速普及。這種環境促進了醫療中心與產業創新者之間的合作，加速了器材的迭代改進和真實世界臨床數據（REW）的產生。

本文旨在介紹推動心房中膈缺損症治療領域技術進步和協作模式的市場領導和新興創新者。

心房中膈缺損症治療方案的競爭格局呈現出老牌醫療設備製造商與靈活敏捷的新興參與企業的局面。憑藉著深厚的臨床關係和廣泛的分銷網路，現有企業不斷改進器械設計和輸送系統。這些改進通常著重於提升器材的貼合度、縮小體積以及在植入過程中整合即時影像回饋。

為改善市場定位、促進創新和提高心房中膈缺損症。

產業領導企業應優先投資於微創器械平台，以降低手術複雜性並改善患者復原。透過將研發資源集中於生物相容性材料和新一代給藥系統，企業可以實現產品差異化並滿足尚未滿足的市場需求。此外，與契約製造製造商和物流專家建立策略夥伴關係，有助於在不斷變化的貿易政策中增強供應鏈的韌性。

綜合調查方法，包括與主要相關人員的對話、對二手資料的審查以及嚴格的資料檢驗過程。

本分析基於嚴謹的研究框架，結合了第一手和第二手調查。第一手調查包括對介入性心臟病專家、心胸外科醫師、採購負責人、保險公司和醫療機構管理人員進行結構化訪談和問卷調查，旨在了解醫療設備表現、臨床工作流程和經濟效益的真實觀點。此外，由臨床專家組成的共識小組對調查結果進行了補充，以檢驗關鍵發現並解讀新出現的趨勢。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：心房中膈缺損症市場：依產品類型分類

  • 心肺體外迴圈裝置
  • 閉合裝置
    • 關閉裝置
      • 球囊式閉合裝置
      • 自膨脹式閉塞裝置
    • 外科補片
      • 生物貼片
      • 合成貼片
  • 診斷設備
    • 心臟導管插入設備
    • 心臟影像系統
    • 心臟超音波圖系統

第9章：心房中膈缺損症市場：依治療方法分類

  • 介入治療
  • 非介入治療

第10章：心房中膈缺損症市場：依年齡層別分類

  • 成人
  • 兒童
    • 青春期
    • 嬰兒
    • 新生

第11章：心房中膈缺損症市場：依最終用戶分類

  • 門診手術中心
  • 心臟中心
  • 醫院

第12章：心房中膈缺損症市場：依缺損類型分類

  • 冠狀竇
  • 第一洞
  • 第二洞
  • 靜脈竇

第13章：心房中膈缺損症市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：心房中膈缺損症市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：心房中膈缺損症市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國心房中膈缺損症市場

第17章：中國心房中膈缺損症市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Asklepion Pharmaceuticals, LLC
  • atHeart Medical AG
  • B. Braun Medical Inc.
  • Boston Scientific Corporation
  • Carag AG
  • Edwards Lifesciences
  • GE HealthCare Technologies, Inc.
  • Koninklijke Philips NV
  • Lepu Medical Technology（Beijing）Co., Ltd
  • Lifetech Scientific
  • Occlutech GmbH
  • Visionary Medtech Solutions
  • WL Gore & Associates, Inc.
  • Weigao Meidcal international Co., Ltd
Product Code: MRR-CA17E905E9C1

The Atrial Septal Defect Market was valued at USD 4.27 billion in 2025 and is projected to grow to USD 4.58 billion in 2026, with a CAGR of 7.53%, reaching USD 7.10 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.27 billion
Estimated Year [2026] USD 4.58 billion
Forecast Year [2032] USD 7.10 billion
CAGR (%) 7.53%

Laying the Foundation for Atrial Septal Defect Market Understanding Through Deep Dive into Clinical, Technological, and Patient Dynamics

Atrial septal defect represents one of the most prevalent congenital heart anomalies encountered in clinical practice, presenting an intricate interplay of hemodynamic, anatomical, and patient-specific factors. Patients with this defect often experience a spectrum of clinical manifestations, ranging from asymptomatic presentations to compromised exercise tolerance, arrhythmias, and right ventricular overload. These diverse patient journeys underscore the critical need for precise diagnostic pathways and tailored therapeutic interventions.

Advancements in diagnostic modalities, including enhancements in intracardiac echocardiography, sophisticated imaging software, and catheterization techniques, have facilitated earlier and more accurate detection of septal defects. At the same time, novel occlusion devices and bioengineered patches are redefining the interventional landscape, offering less invasive options and reduced recovery times. This technological momentum is paralleled by evolving clinical guidelines, which increasingly emphasize patient stratification based on defect size, anatomical location, and comorbid conditions.

Beyond technological and clinical progress, the economic and regulatory backdrop shapes the innovation trajectory. Healthcare payers and regulatory bodies are driving value-based reimbursement frameworks that reward demonstrable improvements in patient outcomes. Consequently, manufacturers and healthcare providers must align research and development initiatives with real-world evidence generation, forging a nexus between clinical efficacy and cost efficiency. This introductory overview sets the stage for a deeper exploration of transformative shifts, policy impacts, and actionable strategies within the atrial septal defect market.

Transformative Shifts Reshaping the Atrial Septal Defect Ecosystem Driven by Innovation, Policy Evolution, and Patient-Centric Care Strategies

The atrial septal defect market is undergoing transformative shifts propelled by breakthroughs in device engineering, shifts in reimbursement paradigms, and an intensified focus on patient-centered care models. Device innovators are pushing the boundaries of miniaturization and biocompatibility, incorporating advanced polymer composites and shape-memory alloys that conform seamlessly to septal anatomy. Simultaneously, the integration of digital health tools-ranging from remote hemodynamic monitoring to AI-enhanced imaging analyses-is enabling clinicians to personalize procedural plans and optimize follow-up protocols.

Concurrently, regulatory authorities in key markets are adopting more streamlined approval pathways for next-generation devices, contingent upon robust post-market surveillance and real-world data collection. These adjustments aim to balance rapid patient access with long-term safety validation. Payer ecosystems are realigning their criteria to support interventions that demonstrate quantifiable reductions in hospital readmissions and improved quality-adjusted life years. Value-based contracting models are incentivizing providers to prioritize durable, cost-effective solutions that deliver sustained clinical benefits.

Moreover, patient advocacy groups and multidisciplinary care teams are elevating the voice of patients in treatment planning, fostering shared decision-making frameworks. This patient empowerment trend underscores the importance of educational initiatives and transparent risk-benefit communication. Together, these transformative forces are reshaping the atrial septal defect landscape from a siloed, procedure-focused environment into an interconnected ecosystem centered on patient outcomes, evidence generation, and integrated care delivery.

Assessing the Impact of United States Tariffs in 2025 on Device Supply Chains, Cost Structures, and Strategic Market Positioning for Cardiac Interventions

The introduction of new tariff structures by the United States in 2025 has introduced a pivotal variable into the supply chain calculus for atrial septal defect devices. By imposing incremental duties on imported components and finished products, manufacturers are encountering elevated costs that reverberate from raw-material procurement through final device assembly. In response, leading device producers are reassessing their sourcing strategies, forging partnerships with regional suppliers to mitigate exposure to duty fluctuations and ensure continuity of component availability.

These strategic shifts are accompanied by renegotiations of commercial agreements with contract manufacturers and logistics providers, aiming to absorb or distribute tariff-related cost pressures. Some stakeholders have accelerated investments in domestic manufacturing capabilities, seeking to qualify for tariff exemptions associated with localized production. While these initiatives may require significant upfront capital, they promise resilience against future trade policy volatility and may unlock incentives tied to domestic job creation.

On the clinical front, hospitals and surgical centers are recalibrating purchasing committees and budget allocations to accommodate the revised cost profiles. Procurement teams are engaging in more rigorous total cost of ownership analyses, balancing device efficacy against lifecycle maintenance and potential tariff escalations. This collective realignment underscores a broader trend: the convergence of trade policy considerations with strategic supply chain management and fiscal stewardship.

Unveiling Key Segmentation Insights into Product Types, Treatment Modalities, Age Demographics, End Users, and Defect Variants in the ASD Arena

In-depth segmentation analysis reveals the multifaceted nature of the atrial septal defect market. When examined through the lens of product type, the landscape comprises cardiopulmonary bypass devices, closure devices, and diagnostic equipment. Within closure solutions, occluder devices stand alongside surgical patches; the former category breaks down further into balloon-expandable and self-expanding variants, while patches may be derived from biologic or synthetic materials. Diagnostic capabilities span cardiac catheterization equipment, advanced imaging systems, and dedicated echocardiography platforms. This layered hierarchy underscores the importance of targeted innovation across distinct technology clusters.

Treatment modalities further refine the market, splitting into interventional and non-interventional approaches. Interventional therapies harness catheter-based technologies and device implants to achieve defect closure with minimal invasiveness, whereas non-interventional options focus on pharmacologic management and monitoring to address hemodynamic burden. Age stratification also plays a defining role: adult and pediatric cohorts exhibit divergent clinical trajectories, with the latter subdivided into neonatal, infant, and adolescent categories, each with unique anatomical and physiological considerations.

End users span ambulatory surgical centers, dedicated cardiac centers, and hospital settings, reflecting varying infrastructure requirements and patient acuity levels. Defect type segmentation highlights coronary sinus, ostium primum, ostium secundum, and sinus venosus anomalies, each necessitating specialized therapeutic frameworks. Understanding these intersecting segmentation dimensions is critical for stakeholders seeking to tailor product development, direct clinical education, and refine market entry strategies.

Decoding Regional Variations in Atrial Septal Defect Markets Across Americas, Europe, Middle East & Africa, and Asia-Pacific Landscapes

Regional dynamics in the atrial septal defect space exhibit notable heterogeneity. In the Americas, well-established reimbursement pathways and early adopter institutions support rapid assimilation of cutting-edge device technologies, coupled with robust clinical trial networks. This environment fosters collaborative partnerships between medical centers and industry innovators, accelerating iterative device enhancements and real-world evidence generation.

Across Europe, the Middle East, and Africa, regulatory landscapes vary widely, from the European Union's centralized approval systems to region-specific health authority processes. This diversity presents both challenges and opportunities; agile manufacturers can navigate these processes by aligning on harmonized clinical dossiers while engaging with regional regulatory experts. Moreover, emerging markets within this zone show increasing adoption of minimally invasive therapies as healthcare infrastructure expands.

In the Asia-Pacific realm, rapid healthcare investment is driving capacity growth in tertiary care facilities, especially in urban centers. Yet cost-containment pressures remain prominent, prompting local manufacturers and multinational corporations to pursue tiered pricing models and technology transfers. Digital health initiatives, including teleconsultation and remote monitoring platforms, are also gaining traction, offering pathways to bridge resource gaps and extend specialist expertise to broader patient populations. These diverse regional contours highlight the imperative for tailored market approaches that resonate with local clinical, economic, and regulatory contexts.

Profiling Market Leaders and Emerging Innovators Driving Technological Advances and Collaborative Approaches in Atrial Septal Defect Management

The competitive arena for atrial septal defect solutions is characterized by a blend of established medical device companies and agile newcomers. Incumbent firms have leveraged deep clinical relationships and expansive distribution networks to introduce iterative upgrades in device design and delivery systems. These upgrades often focus on enhancing device conformability, reducing profile size, and integrating real-time imaging feedback during implantation.

At the same time, emerging players are capturing attention through disruptive innovations such as bioresorbable occluders and next-generation polymer patches that promote tissue regeneration. Collaborative preclinical studies with academic institutions are underpinning these advances, providing critical safety and efficacy data. Additionally, there is a discernible shift toward digital integration, with companies embedding sensor technologies and connectivity features into their devices to support remote monitoring and patient engagement applications.

Strategic alliances, joint ventures, and selective acquisitions have become commonplace as organizations strive to fortify their product portfolios and accelerate entry into adjacent markets. This collaborative ecosystem is fostering cross-disciplinary R&D efforts that marry materials science, engineering prowess, and clinical insights. As a result, the market is witnessing a proliferation of modular solutions that offer scalability across clinical settings, from pediatric catheterization labs to high-throughput surgical suites.

Actionable Strategic Recommendations to Elevate Market Positioning, Foster Innovation, and Enhance Patient Outcomes in Atrial Septal Defect Care

Industry leaders should prioritize investment in minimally invasive device platforms that reduce procedural complexity and enhance patient recovery trajectories. By channeling R&D resources toward bioadaptive materials and next-generation delivery systems, organizations can differentiate their product offerings and address unmet clinical needs. Furthermore, forging strategic partnerships with contract manufacturers and logistics specialists will bolster supply chain resilience amid shifting trade policies.

Parallel to product innovation, developing comprehensive real-world evidence frameworks is essential. This requires collaboration with key opinion leaders, registry coordinators, and payers to capture longitudinal patient outcomes and cost metrics. Demonstrating sustained value through outcomes data will facilitate adoption in value-based reimbursement models and reinforce clinical trust.

Engaging patient advocacy groups and multidisciplinary care teams early in the development cycle can refine product design and ensure alignment with patient priorities. Finally, exploring geographic expansion opportunities in high-growth regions demands customized market access strategies that respect local regulatory nuances and affordability dynamics. Implementing these recommendations will position organizations to navigate market complexities, foster clinician partnerships, and ultimately deliver superior care for patients with atrial septal defects.

Comprehensive Research Methodology Integrating Primary Stakeholder Engagement, Secondary Literature Review, and Rigorous Data Validation Processes

This analysis is grounded in a rigorous research framework combining primary and secondary methodologies. Primary research involved structured interviews and surveys with interventional cardiologists, cardiothoracic surgeons, procurement specialists, payers, and healthcare administrators to capture real-world perspectives on device performance, clinical workflows, and economic considerations. These insights were complemented by consensus panels with clinical experts to validate key findings and interpret emerging trends.

Secondary research encompassed an exhaustive review of peer-reviewed journals, regulatory filings, conference proceedings, patent databases, and company disclosures to construct a robust evidence base. Publicly available healthcare datasets and procedural registries were interrogated to identify utilization patterns and geographic adoption curves. Data triangulation techniques were applied throughout to reconcile discrepancies between sources and enhance the credibility of conclusions.

Quality control processes included systematic cross-validation of quantitative data points and iterative reviews by an internal research governance committee. Expert validation workshops provided additional scrutiny, ensuring that assumptions, segmentation frameworks, and strategic recommendations reflect the current state of the atrial septal defect market and are poised to withstand future shifts.

The landscape of atrial septal defect management is defined by concurrent forces of innovation, policy evolution, and shifting patient expectations. Advancements in device engineering and diagnostic modalities continue to drive clinical adoption, while evolving reimbursement frameworks are incentivizing tangible improvements in long-term patient outcomes. Supply chain realignments, influenced by recent trade policy changes, underscore the importance of agility and domestic capability expansion to mitigate cost pressures.

Segmentation insights highlight the multifaceted nature of this market, from diverse product categories and treatment pathways to nuanced age and defect-type considerations. Regional analyses reveal distinct growth drivers and access barriers, necessitating tailored approaches in the Americas, Europe, Middle East & Africa, and Asia-Pacific contexts. Meanwhile, the interplay between established players and emerging innovators is catalyzing collaborative advances that align engineering breakthroughs with clinical evidence.

Collectively, these insights form an integrated perspective on market dynamics, strategic imperatives, and areas of opportunity. Organizations that embrace data-driven decision-making, cultivate stakeholder partnerships, and invest in patient-centric innovation are best positioned to thrive in this evolving ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Atrial Septal Defect Market, by Product Type

  • 8.1. Cardiopulmonary Bypass Devices
  • 8.2. Closure Devices
    • 8.2.1. Occluder Devices
      • 8.2.1.1. Balloon-Expandable Occluders
      • 8.2.1.2. Self-Expanding Occluders
    • 8.2.2. Surgical Patches
      • 8.2.2.1. Biologic Patches
      • 8.2.2.2. Synthetic Patches
  • 8.3. Diagnostic Devices
    • 8.3.1. Cardiac Catheterization Equipment
    • 8.3.2. Cardiac Imaging Systems
    • 8.3.3. Echocardiography Systems

9. Atrial Septal Defect Market, by Treatment Type

  • 9.1. Interventional Treatment
  • 9.2. Non-Interventional Treatment

10. Atrial Septal Defect Market, by Age Group

  • 10.1. Adult
  • 10.2. Pediatric
    • 10.2.1. Adolescent
    • 10.2.2. Infant
    • 10.2.3. Neonatal

11. Atrial Septal Defect Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Cardiac Centers
  • 11.3. Hospitals

12. Atrial Septal Defect Market, by Defect Type

  • 12.1. Coronary Sinus
  • 12.2. Ostium Primum
  • 12.3. Ostium Secundum
  • 12.4. Sinus Venosus

13. Atrial Septal Defect Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Atrial Septal Defect Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Atrial Septal Defect Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Atrial Septal Defect Market

17. China Atrial Septal Defect Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Asklepion Pharmaceuticals, LLC
  • 18.7. atHeart Medical AG
  • 18.8. B. Braun Medical Inc.
  • 18.9. Boston Scientific Corporation
  • 18.10. Carag AG
  • 18.11. Edwards Lifesciences
  • 18.12. GE HealthCare Technologies, Inc.
  • 18.13. Koninklijke Philips N.V.
  • 18.14. Lepu Medical Technology (Beijing) Co., Ltd
  • 18.15. Lifetech Scientific
  • 18.16. Occlutech GmbH
  • 18.17. Visionary Medtech Solutions
  • 18.18. W. L. Gore & Associates, Inc.
  • 18.19. Weigao Meidcal international Co., Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ATRIAL SEPTAL DEFECT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ATRIAL SEPTAL DEFECT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ATRIAL SEPTAL DEFECT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ATRIAL SEPTAL DEFECT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY CARDIOPULMONARY BYPASS DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY CARDIOPULMONARY BYPASS DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY CARDIOPULMONARY BYPASS DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY BALLOON-EXPANDABLE OCCLUDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY BALLOON-EXPANDABLE OCCLUDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY BALLOON-EXPANDABLE OCCLUDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY SELF-EXPANDING OCCLUDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY SELF-EXPANDING OCCLUDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY SELF-EXPANDING OCCLUDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY BIOLOGIC PATCHES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY BIOLOGIC PATCHES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY BIOLOGIC PATCHES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYNTHETIC PATCHES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYNTHETIC PATCHES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY SYNTHETIC PATCHES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY CARDIAC CATHETERIZATION EQUIPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY CARDIAC CATHETERIZATION EQUIPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY CARDIAC CATHETERIZATION EQUIPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY CARDIAC IMAGING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY CARDIAC IMAGING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY CARDIAC IMAGING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY ECHOCARDIOGRAPHY SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY ECHOCARDIOGRAPHY SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY ECHOCARDIOGRAPHY SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY INTERVENTIONAL TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY INTERVENTIONAL TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY INTERVENTIONAL TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY NON-INTERVENTIONAL TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY NON-INTERVENTIONAL TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY NON-INTERVENTIONAL TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY ADOLESCENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY ADOLESCENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY INFANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY INFANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY INFANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY NEONATAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY NEONATAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY NEONATAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY CARDIAC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY CARDIAC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY CARDIAC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY CORONARY SINUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY CORONARY SINUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY CORONARY SINUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY OSTIUM PRIMUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY OSTIUM PRIMUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY OSTIUM PRIMUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY OSTIUM SECUNDUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY OSTIUM SECUNDUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY OSTIUM SECUNDUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY SINUS VENOSUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY SINUS VENOSUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY SINUS VENOSUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS ATRIAL SEPTAL DEFECT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE ATRIAL SEPTAL DEFECT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST ATRIAL SEPTAL DEFECT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC ATRIAL SEPTAL DEFECT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN ATRIAL SEPTAL DEFECT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. GCC ATRIAL SEPTAL DEFECT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. GCC ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. GCC ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 194. GCC ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2018-2032 (USD MILLION)
  • TABLE 195. GCC ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 196. GCC ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 197. GCC ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. GCC ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 199. GCC ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 200. GCC ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. GCC ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION ATRIAL SEPTAL DEFECT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS ATRIAL SEPTAL DEFECT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. G7 ATRIAL SEPTAL DEFECT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. G7 ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. G7 ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 227. G7 ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2018-2032 (USD MILLION)
  • TABLE 228. G7 ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 229. G7 ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 230. G7 ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. G7 ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 232. G7 ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 233. G7 ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. G7 ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. NATO ATRIAL SEPTAL DEFECT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 236. NATO ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. NATO ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 238. NATO ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2018-2032 (USD MILLION)
  • TABLE 239. NATO ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 240. NATO ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 241. NATO ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. NATO ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 243. NATO ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 244. NATO ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. NATO ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. GLOBAL ATRIAL SEPTAL DEFECT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES ATRIAL SEPTAL DEFECT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA ATRIAL SEPTAL DEFECT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA ATRIAL SEPTAL DEFECT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA ATRIAL SEPTAL DEFECT MARKET SIZE, BY CLOSURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA ATRIAL SEPTAL DEFECT MARKET SIZE, BY OCCLUDER DEVICES, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA ATRIAL SEPTAL DEFECT MARKET SIZE, BY SURGICAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA ATRIAL SEPTAL DEFECT MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA ATRIAL SEPTAL DEFECT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA ATRIAL SEPTAL DEFECT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA ATRIAL SEPTAL DEFECT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA ATRIAL SEPTAL DEFECT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA ATRIAL SEPTAL DEFECT MARKET SIZE, BY DEFECT TYPE, 2018-2032 (USD MILLION)